Englander Institute for Precision Medicine

Publications

Found 12 results
Author Title Type [ Year(Asc)]
Filters: Author is Powles, Thomas  [Clear All Filters]
2024
Sridhar SS, Powles T, Durán MÁCliment, Park SHoon, Massari F, Thiery-Vuillemin A, Valderrama BP, Ullén A, Tsuchiya N, Aragon-Ching JB et al..  2024.  Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.. Eur Urol. 85(2):154-163.
2023
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
2022
de Wit R, Powles T, Castellano D, Necchi A, Lee J-L, van der Heijden MS, Matsubara N, Bamias A, Fléchon A, Sternberg CN et al..  2022.  Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.. Br J Clin Pharmacol. 88(7):3182-3192.
Powles T, Park SHoon, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulovic S, Demey W, Ullén A et al..  2022.  Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.. Future Oncol. 18(19):2361-2371.
van der Heijden MS, Powles T, Petrylak D, de Wit R, Necchi A, Sternberg CN, Matsubara N, Nishiyama H, Castellano D, Hussain SA et al..  2022.  Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. Nat Commun. 13(1):1878.
Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JLyun, Fléchon A, Roubaud G, Pouessel D, Zagonel V, Calabrò F et al..  2022.  Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. Eur J Cancer. 163:55-65.
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee J-L, Fong L, Necchi A, Sternberg CN, O'Donnell PH et al..  2022.  Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. Clin Cancer Res. 28(10):2050-2060.
2021
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V et al..  2021.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.. Lancet Oncol. 22(4):525-537.
Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJasmine, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R et al..  2021.  Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.. Nat Med. 27(12):2200-2211.
Merseburger AS, Castellano D, Powles T, Loriot Y, Retz M, Voortman J, Huddart RA, Gedye C, van der Heijden MS, Gurney H et al..  2021.  Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.. J Urol. 206(2):240-251.
2020
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AShivaram, Powles T et al..  2020.  Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. Urol Oncol. 38(12):934.e1-934.e9.